SCHEMBL15465245

SCHEMBL15465245

OC1CCCCC1c1cnn(C2CCCCO2)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 1/20 0.36
CYP4F2 P78329 2/20 0.34
CYP4A11 Q02928 2/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
MCL1 Q07820 1/20 0.33
FLT3 P36888 2/20 0.32
FGFR1 P11362 1/20 0.32
FGFR2 P21802 1/20 0.32
FGFR4 P22455 1/20 0.32
FGFR3 P22607 1/20 0.32
KDR P35968 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
AR P10275 3/20 0.31
SYK P43405 1/20 0.31
AURKB Q96GD4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16290188 1.00 KDM5B (0.36) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL15465247 1.00 KDM5B (0.36) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL15465607 0.99 KDM5B (0.36) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL15465605 0.99 KDM5B (0.36) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL15464441 0.83 KDM5B (0.34) KDM5BCYP4F2CYP4A11
SCHEMBL15464440 0.83 KDM5B (0.34) KDM5BCYP4F2CYP4A11
SCHEMBL25275730 0.81 KDM5B (0.39) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL25232797 0.80 KDM5B (0.39) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL21334765 0.79 KDM5B (0.36) KDM5BCYP4F2CYP4A11ALDH1A1LMNA
SCHEMBL20519095 0.79 KDM5B (0.36) KDM5BCYP4F2CYP4A11ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2974730-B1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO CO LTD (JP) 2018-01-31 EP disclosed
EP-3144300-B1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES DAIICHI SANKYO CO LTD (JP) 2017-12-20 EP disclosed
US-9845313-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-12-19 US disclosed
EP-3144300-A1 METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES Daiichi Sankyo Company, Limited (JP) 2017-03-22 EP disclosed
US-9597330-B2 Drugs for treating respiratory diseases DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-03-21 US disclosed
US-20170001984-A1 CYCLOALKANE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-01-05 US disclosed
US-9493448-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-11-15 US disclosed
EP-2813491-B1 CYCLOALKANE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-11-02 EP disclosed
US-20160038486-A1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-02-11 US disclosed
EP-2974730-A1 DRUG FOR RESPIRATORY DISEASES DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-01-20 EP disclosed
EP-2813491-A1 CYCLOALKANE DERIVATIVE Daiichi Sankyo Co., Ltd. (JP) 2014-12-17 EP disclosed
US-8889741-B2 Cycloalkane derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-11-18 US disclosed
US-20140045862-A1 Cycloalkane Derivatives DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160038486-A1 DRUG FOR RESPIRATORY DISEASES SCN1B, NHERF1, SCNN1A KDM5B 4800/4885CYP4F2 1449/4885CYP4A11 764/4885
US-20170001984-A1 CYCLOALKANE DERIVATIVES TRPV1, TRPA1, SCNN1A KDM5B 4754/4885CYP4F2 2573/4885CYP4A11 2205/4885
US-20140045862-A1 Cycloalkane Derivatives TRPV1, TRPA1, SCNN1A KDM5B 4754/4885CYP4F2 2573/4885CYP4A11 2205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.